← All organizations

Biogen-IDEC

For profitContributed to NME

Also known as: Biogen Idec | BIOGEN IDEC | Biogen Idec, Cambridge, MA USA | Biogen Idec. Contact for more details | BIOGEN IDEC INC | neurologyclinicaltrials@biogenidec.com

Phase 1 Phase 2 Phase 3 Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Sep 29, 2023

Timeline

2000s

Jan 1, 2003
Biogen-IDEC— Founded
Jan 1, 2003
Biogen— Acquired
Jan 1, 2003
IDEC— Acquired
May 3, 2006
Conforma Therapeutics— Acquired
Jan 23, 2007
Syntonix Pharmaceuticals— Acquired

2010s

Feb 14, 2012
Stromedix— Acquired
Aug 15, 2014
peginterferon beta-1a— NDA Secondary Org
Aug 15, 2014
peginterferon beta-1a— Marketing Organization
Jan 1, 2015
Convergence Pharmaceuticals— Acquired
Dec 23, 2016
nusinersen— NDA Organization
Feb 1, 2017
Forward Pharma GmbH— Acquired
May 18, 2017
Remedy Pharmaceuticals, Inc.— Acquired
Mar 4, 2019
NightstaRx Limited— Acquired

2020s

Sep 26, 2023
Reata Pharmaceuticals, Inc.— Acquired

Drugs by trial phase (175 distinct, 483 trials)

Phase 4 (0 own, 29 via acquisition)

Phase 3 (0 own, 39 via acquisition)

Phase 2 (0 own, 56 via acquisition)

Phase 1 (0 own, 50 via acquisition)

Other trials (0 own, 1 via acquisition)

florbetapir

Indications

Approved for

Studied for

Marketed drugs (11)

Subsidiaries (10 direct, 11 total across the full acquisition tree)

Recent trials (5)

NCT01069913Study directorPhase 1Oct 1, 2009
NCT00493077Overall official - principal investigatorPhase 4May 1, 2004
NCT00276172Study chairPhase 3Dec 1, 2003
NCT00492466Overall official - principal investigatorPhase 4Mar 1, 2003
NCT00534261Overall official - principal investigatorPhase 4Nov 1, 1999

Details

Founded: Cambridge, MA, US Jan 1, 2003
First NDA: Nov 23, 2004
Last known activity: Sep 29, 2023

Designations held

Orphan drug
Fast track
Priority review
Accelerated approval